Oncolytic adenoviral vectors selectively replicate in and lyse human tumor cells, providing a promising means for targeted tumor destruction. However, oncolytic vectors have limited capacity for incorporation of additional genetic material that could encode therapeutic transgenes and/or transcriptional regulatory control elements to augment the efficacy and/or safety of the vector. Therefore, we hypothesized that coadministration of an oncolytic vector with a replication-defective, gutless adenoviral vector encoding a therapeutic transgene would result in replication of both vectors within a tumor and potentiate antitumor efficacy relative to the use of either vector alone. We constructed gutless vectors encoding the murine granulocyte-macrophage colonystimulating factor (AGVmGMF) or human tumor necrosis factor a-related apoptosis-inducing ligand (AGVhTRAIL) gene and tested the ability of these vectors to augment the efficacy of an oncolytic vector (Ar6pAE2fE3F) in a potentiating vector strategy. In Hep3B cells in vitro, cotreatment with Ar6pAE2fE3F increased transgene expression from AGVhTRAIL and permitted replication of AGVhTRAIL, suggesting that an oncolytic vector can propagate gutless vector spread in vivo. In pre-established Hep3B xenograft tumors, neither gutless vector alone inhibited tumor growth; however, coadministration of AGVmGMF or AGVhTRAIL with Ar6pAE2fE3F significantly reduced tumor growth relative to Ar6pAE2fE3F alone. Additionally, use of AGVhTRAIL with Ar6pAE2fE3F increased the number of complete or partial tumor regressions observed at study end. These data provide evidence that coadministration of an oncolytic vector with a gutless vector holds promise for potentiating tumor ablation efficacy.
T he development of gene therapies for the treatment of cancer has generally relied upon two strategies. The first is the expression of a therapeutic transgene from a replication-defective (RD) viral vector, whereby the tumor cell is transduced and produces a protein that is intended to provide an antitumor effect. 1 Genes used with this approach have encoded various proteins intended to stimulate a tumor-specific immune response, induce apoptosis, inhibit angiogenesis, reconstitute a defective tumor suppressor pathway or enzymatically activate a cytotoxic pro-drug. One advantage to the use of nonreplicating vectors is the ability to deliver large genetic payloads to target cells due to deletion of viral genes from the vector genome. For example, helper-dependent or gutless adenoviral vectors contain only the inverted terminal repeats (ITRs) and packaging signal of the wild-type viral genome. 2 These vectors have a coding capacity of up to 38 kb, theoretically enabling the delivery of multiple therapeutic genes to target cells. The efficacy of nonreplicating vectors, however, is generally limited by the relatively low level of transgene expression that is achieved due to the small percentage of cells that are transduced within a solid tumor. 3 Continued tumor growth quickly dilutes the cells expressing the transgene and the therapeutic effect.
The second strategy employed for cancer gene therapy involves the engineering of lytic viruses to produce oncolytic gene therapy vectors that selectively replicate in and lyse tumor cells. 4, 5 The primary advantage of replication-competent (RC) oncolytic vectors is that viral replication will amplify the initial input dose, allowing the spread of vector throughout the tumor. Tumor-selective replication is based either on the introduction of loss-offunction mutations in viral genes that are essential for viral replication in normal cells but not tumor cells 6 or on the use of tumor-selective promoters to control transcription of early viral genes essential for viral replication. 7, 8 Oncolytic adenoviral vectors are currently being developed as a novel class of cancer therapeutics using both of these strategies. The oncolytic vector Ar6pAE2fE3F is based on adenovirus serotype 5 (Ad5) and contains the human E2F-1 promoter to drive tumor-selective expression of the E1A gene. 8 The E2F-1 promoter is upregulated in response to loss of function of the retinoblastoma (Rb) tumor suppressor pathway, [9] [10] [11] which occurs in a large percentage of human tumors. 12 The cytotoxic activity of Ar6pAE2fE3F was demonstrated to be selective for Rb pathway defective tumor cells and to correlate with E1A expression. Ar6pAE2fE3F mediated a dramatic inhibition of tumor growth in a human hepatoma xenograft model. Since disruption of Rb pathway signaling occurs at a high frequency in a wide variety of human cancers, 12 these data suggest that this vector could be an effective therapy for multiple tumor types.
The ability to increase oncolytic vector efficacy by exploiting other therapeutic targets using a gene therapy approach would be beneficial. Bristol et al 13 recently demonstrated this point by combining an immunotherapy strategy with oncolytic vector therapy. By deleting all but one of the E3 region genes, the murine granulocytemacrophage colony-stimulating factor (mGMCSF) gene was inserted into Ar6pAE2fE3F to create Ar6-pAE2fmGMF. In this vector, mGMCSF expression was driven by the natural Ad5 E3 promoter and was detectable in tumors injected with the vector. At the highest dose, Ar6pAE2fmGMF caused complete regression of 60 and 40% of H460 and Hep3B xenograft tumors, respectively. For comparison, treatment with the parent vector, lacking the mGMCSF gene, resulted in complete regression of only 10% of H460 and 0% of Hep3B tumors. These results provide evidence that the integration of an additional therapeutic strategy into oncolytic vector therapy could increase antitumor efficacy. Additionally, these observations raise the possibility that combining multiple gene therapy approaches could increase the therapeutic potential even further.
''Arming'' adenoviral oncolytic vectors with therapeutic transgenes, however, may be problematic. For example, due to the requirement for the presence of most viral genes to allow replication, oncolytic vectors have limited capacity for additional genetic material. As a result, viral genes that are not absolutely necessary for viral replication are often deleted to accommodate a new transgene. Frequently, the area chosen to insert additional genes has been in the E3 region of the Ad5 genome, because genes in this region are dispensible for viral replication.
14 However, it is becoming clear that the E3 region augments vector function and increases antitumor efficacy. 15, 16 The potentiation of oncolytic vector function by direct ''arming'' may, therefore, necessitate balancing the gain of vector function by inclusion of the therapeutic transgene with the loss of function by deletion of viral genes. This likelihood will almost certainly hamper the ability to include multiple therapeutic transgenes and/or transcriptional regulatory elements. These facts led us to test whether a two-vector system using a gutless adenoviral vector could potentiate oncolytic adenoviral vector function.
We investigated whether the combination of Ar6pAE2-fE3F with an RD, gutless adenoviral vector encoding a therapeutic transgene could increase antitumor efficacy by allowing the use of multiple therapeutic strategies simultaneously. Production of RD adenoviral vectors is performed in the presence of an RC helper virus, which provides the viral proteins to allow replication and packaging of the defective vector.
2 It is, therefore, possible that cotransduction of a tumor cell with both a gutless vector and an oncolytic vector would result in the propagation of both vectors and their spread within the tumor mass. Additionally, replication of the gutless vector genome could lead to increased expression of its transgene prior to cell lysis, thereby overcoming the primary limitation to using an RD vector alone. In a recent study, an RC Ad5 vector was coadministered with an earlygeneration RD vector encoding the luciferase gene. 17 At 2 weeks following intratumoral injections, Hep3B xenograft tumors which received both the RC vector and the RD vector contained 22-fold greater luciferase activity than Hep3B tumors injected with only the RD vector, suggesting increased transgene expression, vector spread, or both. An additional experiment in A549 xenograft tumors suggested that the RD vector did indeed spread throughout the tumor. Therefore, it is possible that the combination of a gutless vector expressing a transgene(s), which exhibits antitumor activity, and an oncolytic vector could provide better antitumor efficacy than the use of either vector alone.
In the current study, we tested whether a gutless adenoviral vector containing a single therapeutic transgene would potentiate the efficacy of the oncolytic adenoviral vector Ar6pAE2fE3F in Hep3B tumor xenografts. Gutless vectors were generated that encoded either mGMCSF or human tumor necrosis factor (TNF)-related apoptosis-inducing ligand (hTRAIL). mGMCSF is a cytokine with a broad spectrum of immunostimulatory effects and is reported to induce specific, long-lasting antitumoral immunity. 18 hTRAIL is a TNF-a family member that induces apoptosis selectively in tumor cells and has been shown to exhibit antitumor activity with little apparent toxicity. [19] [20] [21] [22] In vitro analyses demonstrated that cotransduction of Hep3B cells with oncolytic and gutless vectors resulted in amplification of gutless vector transgene expression and production of functional gutless vector progeny. Following intratumoral delivery of the vector pair to Hep3B xenograft tumors, improved antitumor efficacy was achieved relative to treatment with either vector alone. These results provide positive evidence that gutless adenoviral vectors may be efficacious to potentiate oncolytic vector function for cancer therapies.
Materials and methods

Adenoviral vectors
Gutless adenoviral vector plasmids were generated by cloning transgene expression cassettes into the pGTI. 24aPL2 shuttle vector. pGTI.24aPL2 contains a multiple cloning site flanked by human synuclein stuffer sequence on either side. 23 The synuclein stuffer used was a 22 kb fragment isolated from the first intron of the human alpha-synuclein gene, and was AT-rich (65%). We found that the high adenine and thymine content served to diminish the density of the gutless adenoviral vector, thereby improving vector purity via density gradient ultracentrifugation. The resulting plasmids were called pGTImGMCSF and pGTIEF1hTRAIL. Shuttle plasmids were linearized with PacI and combined with pBV2 23 to generate the gutless vector plasmids pAGVmGMF and pAGVEF1hTRAIL. Vectors were generated by transfecting 5À150 mm plates of Per.C6-Cre cells with B40À50 mg/plate of linearized plasmid DNA using the Profection Calcium Phosphate Mammalian Transfection System (Promega, Madison, WI). Per.C6-Cre cells are based on Per.C6 cells 24 and have been modified to express constitutively Cre recombinase. 23 The next day, cells were transduced with 100 particles per cell (PPC) of the Av1S4BflxFE3 helper virus. 23 Viral vector was harvested when complete cytopathic effect (CPE) was evident, normally 40À48 hours after helper virus addition. The cleared viral lysate (CVL) was made by lysing cells with three freeze/thaw cycles and pelleting the resulting cellular debris. CVL was used to transduce 10À150 mm plates with helper virus supplementation at 50 PPC. The CVL from this transduction was then used to transduce 30À150 mm plates with helper virus supplementation. Gutless vectors were then purified from the 30 plate CVL by CsCl gradient centrifugation. This gutless vector preparation was then used as a seed lot for further gutless vector amplification in PerC6-Cre cells. AGVmGMF contained the murine GMCSF coding region with the CMV immediate-early enhancer/promoter and SV40 polyadenylation (pA) sequence from pCI (Promega). AGVhTRAIL contained the complete human TRAIL coding region with the human elongation factor-1 alpha (EF-1a)/human T-cell leukemia virus (HTLV) promoter from pORF (Invivogen, San Diego, CA) and SV40 pA sequence. AGVnull contained no expression cassette. 25 Gutless vector preparations did not contain RC adenovirus, and helper virus contamination levels were as measured by real-time PCR. 23, 24 Helper virus contamination in gutless vector preps was less than 1%.
The construction of Ar6pAE2fE3F was described previously. 8 Briefly, the packaging signal and E1A promoter were removed from the left end of the Ad5 genome and replaced with an SV40 early pA sequence from pSVSPORT1 (Life Technologies, Rockville, MD) and a 273 bp fragment of the human E2F-1 promoter. The packaging signal was inserted upstream of the right ITR. This vector contains all of the E3 coding regions of the Ad5 genome with the exception of the 14.7 K protein. Ar6pAE2fmGMF was created from Ar6pAE2fE3F by deleting a portion of the E3 region and leaving only the 12.5 K protein coding sequence as described previously. 13 The murine GMCSF gene was inserted 3 0 to the 12.5 K gene, such that transcription of GMCSF is regulated by the E3 promoter. Vector concentrations were determined by spectrophotometry as described previously. 26 
Cell culture
Hep3B cells were obtained from ATCC and maintained in EMEM (Invitrogen) þ 10% fetal bovine serum (FBS; Bio Whittaker, Walkersville, MD). All adenoviral vector transductions were performed in EMEM þ 1% FBS on confluent cultures. To confirm the expression of murine GMCSF from AGVmGMCSF, conditioned growth medium was assayed by enzyme-linked immunosorbent assay (ELISA; R&D System, Minneapolis, MN). Expression of human TRAIL from AGVhTRAIL was confirmed by ELISA with the Soluble TRAIL/Apo2L ELISA Kit (Diaclone, France) using cell lysates made in Reporter Lysis Buffer (Promega). The concentrations obtained using this ELISA kit were multiplied by a factor of 1.66 to correct for the difference in molecular weight between full-length TRAIL (32.5 kDa) and recombinant, soluble TRAIL (19.6 kDa). The total concentration of protein in cell lysates was determined using the BCA Protein Assay (Pierce, Rockford, IL). To determine the cytotoxicity of TRAIL, Hep3B cells were transduced with AGVhTRAIL or treated with recombinant, soluble human TRAIL (R&D Systems) in quintuplicate, and at the indicated times, cell viability was measured using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer's instructions.
To determine whether oncolytic vectors can complement the propagation of gutless vectors, confluent 100 mm plates of Hep3B cells were treated with the indicated vectors in EMEM þ 1% FBS. After 4 hours, the medium was aspirated, plates were rinsed once with sterile phosphate-buffered saline, and cells were refed with EMEM þ 10% FBS. When the CPE was present, crude viral lysate (CVL) was prepared. Confluent 100 mm plates of Hep3B cells were then transduced with 10 ml of CVL in 10 ml EMEM þ 1% FBS. After 24 hours, cell lysates were prepared and assayed for hTRAIL by ELISA as described earlier.
Animal studies
A total of 1 Â 10 7 Hep3B cells in 100 ml HBSS were seeded subcutaneously in female Balb c nu/nu mice on the right flank. Once tumors reached approximately 100 mm 3 , animals were randomized into treatment groups. Vectors were diluted in HBSS and administered by intratumoral injection (50 ml) once every other day, excluding weekends, for a total of five injections. At 72 hours following the initial vector injection, serum was collected from mice that received a vector containing the GMCSF transgene or an appropriate control vector by retro-orbital bleed. The concentration of murine GMCSF in serum was determined by ELISA as described above. Tumor measurements were performed twice weekly and tumor volumes were estimated using the formula (p Â length Â width 2 )/6. A subset of animals (n ¼ 3) were euthanized 72 hours after the initial vector injection to determine the concentration of GMCSF or TRAIL in tumors. Frozen tumors were lysed in Reporter Lysis Buffer (Promega) at 100 mg/ml, and the concentration of murine GMCSF or human TRAIL was determined by ELISA as described earlier. Animals that became moribund or that harbored tumors in excess of 2000 mm 3 were removed from the study and euthanized according to the IACUC protocol. Studies were terminated when all the remaining animals harbored tumors less than 100 mm 3 . Tumor volumes were transformed using the formula (tumor volume þ 3/8) 0.5 and subject to one-way analysis of variance (ANOVA). The duration of time animals were on study was analyzed by the KaplanÀMeier method and log-rank test. Differences in the number of animals remaining on study at a particular time were analyzed using Fisher's exact test.
All the animals were cared for and maintained in accordance with applicable US Animal Welfare regulations under an approved Institutional Animal Care and Use Protocol in Genetic Therapy, Inc.'s animal facility, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
Results
To test whether coadministration of an RD gutless adenoviral vector encoding a therapeutic transgene would potentiate the efficacy of the oncolytic vector Ar6pAE2-fE3F, we constructed two gutless vectors encoding the murine GMCSF or human TRAIL genes driven by constitutive promoters. Schematics of the vectors used in this study are illustrated in Figure 1 . AGVmGMF and AGVhTRAIL were tested in vitro to ensure that transgene expression was induced upon cell transduction. Hep3B cells transduced with AGVmGMF secreted GMCSF at high levels into the growth medium in a dose-dependent manner (Fig 2) . Likewise, transduction of Hep3B cells with AGVhTRAIL resulted in a dose-dependent increase in TRAIL expression (Fig 3a) . To verify that TRAIL was biologically active and could kill Hep3B cells in culture, cell viability was determined following transduction with AGVhTRAIL alone. Exposure of cells to AGVhTRAIL resulted in a dose-dependent reduction in cell viability, with only 2% of cells treated at 500 PPC remaining viable after 9 days (Fig 3b) . In comparison, transduction with a gutless vector containing no expression cassette (AGVnull) at the same PPC caused only a minimal decrease in cell viability over the course of the experiment. Interestingly, treatment of Hep3B cells with recombinant, soluble TRAIL protein at a very high dose of 250 ng/ml decreased viability to only 66% on day 2. Viability then returned to near 100% after 9 days exposure, suggesting that the cytotoxic effect of a single dose of soluble TRAIL was transient, after which cells regrew to reach confluence.
To determine what effect an oncolytic adenoviral vector would have on gutless vector expression and replication, we transduced Hep3B cells with AGVhTRAIL and the oncolytic adenoviral vector Ar6pAE2fE3F. Cotransduction of confluent cultures with both AGVhTRAIL and Ar6pAE2fE3F resulted in a 25-fold greater concentration of TRAIL in cells 48 hours after transduction than treatment with AGVhTRAIL alone (Fig 4) . Increased expression of TRAIL was not observed when cells were treated with the combination of AGVhTRAIL and the RD vector AGVnull. Protein lysates from cells that were untreated or transduced with Ar6pAE2fE3F, AGVnull or 8 Ar6pAE2fmGMF contains the same E2F-1 promoter fragment and the murine GMCSF coding region driven by the viral E3 promoter. 13 The gutless adenoviral vectors AGVmGMF and AGVhTRAIL contain only the left and right ITRs and packaging signal of the wild-type viral genome. AGVmGMF contains the murine GMCSF coding region driven by the immediate-early CMV promoter. AGVhTRAIL contains the coding sequence for the full-length human TRAIL protein driven by an EF-1/HTLV promoter. a combination of these two vectors did not contain detectable levels of TRAIL.
In addition to increasing gutless vector transgene expression, treatment with both Ar6pAE2fE3F and AGVhTRAIL resulted in the production of gutless vector progeny that were capable of transducing a second round of cells (Table 1) . Measurement of the concentration of TRAIL in Hep3B cells after treatment for 24 hours with the CVL from a previous transduction containing both Ar6pAE2fE3F and AGVhTRAIL revealed high levels of the protein. TRAIL was not detected in cells treated with the CVL from initial transductions of Ar6pAE2fE3F or AGVhTRAIL alone, indicating that gutless vector progeny were not produced unless cells were transduced with both vectors. These data demonstrate that the oncolytic vector functioned as a helper virus in the replication and propagation of the gutless vector and suggest that the oncolytic vector could replace the E1-deficient helper virus in gutless vector generation and scale-up procedures.
The potential benefit of coadministration of a gutless vector with an oncolytic vector was assessed in preestablished Hep3B xenograft tumors growing subcutaneously in nude mice. An initial study was performed to assess the antitumor effect of different ratios of the oncolytic vector Ar6pAE2fE3F and the gutless vector AGVmGMF. Figure 5 shows the mean tumor volume (n ¼ 6) on day 16 following five intratumoral injections of the indicated treatments given every other day. Ar6pAE2-fE3F at a dose of 2 Â 10 7 particles per injection (ppi) decreased tumor volume by 43% relative to HBSS, while a dose of 4 Â 10 7 ppi reduced tumor volume by 83%. In comparison, an RD vector Addl312 lacking the E1A coding region given at a dose of 4 Â 10 7 ppi exhibited no antitumor effect. AGVmGMF was admininstered with Ar6pAE2fE3F at ratios of 4:1 and 1:1 (oncolytic:gutless), while holding the number of particles of oncolytic vector constant at 2 Â 10 7 ppi. AGVmGMF given at a 1:1 ratio with the oncolytic vector did not significantly slow tumor growth relative to a matched dose of Ar6pAE2fE3F alone. However, the 4:1 ratio of oncolytic:gutless decreased tumor volume 93% relative to HBSS-treated tumors. This result was statistically different from tumors treated with HBSS or oncolytic vector alone at a dose of 2 Â 10 7 ppi (Po.001). In fact, the mean volume of tumors treated with the combination of oncolytic and gutless vectors at a 4:1 ratio was 40% of the volume of tumors treated with oncolytic vector at the higher dose of 4 Â 10 7 ppi. This difference, however, did not reach statistical significance (P4.05). Injection of tumors with AGVmGMV alone at a dose of 4 Â 10 7 ppi had no effect on tumor volume relative to HBSS. These data demonstrate that the increased efficacy of the oncolytic plus gutless vector group was due to an additive effect rather A second study containing 15 animals/treatment group was then undertaken to determine the effects of AGVmGMF and AGVhTRAIL in a potentiating vector strategy. Animals received five intratumoral injections on an every other day schedule. Ar6pAE2fE3F was administered at a dose of 2 Â 10 7 ppi alone or with AGVmGMF or AGVhTRAIL at a 4:1 ratio (oncolytic:gutless). AGVhTRAIL was also tested alone at a dose of 2 Â 10 7 ppi. For comparison, the RC oncolytic vector Ar6pAE2fmGMF, which contains the murine GMCSF coding region under the control of the E3 promoter, was included. This vector was previously shown to mediate GMCSF expression from Hep3B cells in vitro and in vivo and to exhibit enhanced antitumor effects relative to the parent vector, which lacks the GMCSF transgene. 13 All treatments that included a replicating oncolytic vector decreased the rate of tumor growth (Fig 6) and increased the duration of time animals were on study (Table 2) relative to HBSS or the RD vector, Addl312. The presence of the GMCSF gene in vector treatments, whether expressed from the oncolytic vector Ar6-pAE2fmGMF or the gutless vector AGVmGMF in combination with Ar6pAE2fE3F, decreased the rate of tumor growth compared to Ar6pAE2fE3F alone. Differences in tumor volumes between Ar6pAE2fE3F and Ar6pAE2fmGMF or Ar6pAE2fE3F þ AGVmGMF were statistically significant (Po0.05) on days 6-20 following initiation of vector administration. However, there was no significant difference between tumors treated with Ar6-pAE2fmGMF and Ar6pAE2fE3F þ AGVmGMF. AGVhTRAIL also decreased the growth rate of Hep3B tumors when administered as a potentiating vector with Ar6pAE2fE3F. The time needed for mean tumor volume to reach 400 mm 3 was approximately doubled when tumors were injected with both vectors compared to Ar6pAE2fE3F alone. On study days 6, 10 and 20, the mean volume of tumors treated with Ar6pAE2-fE3F þ AGVhTRAIL was significantly less than tumors treated with Ar6pAE2fE3F alone (Po.05). Another group of tumor-bearing mice received 2 Â 10 7 ppi of AGVhTRAIL alone. Similar to treatment with AGVmGMF alone (Fig 5) , AGVhTRAIL alone did not exhibit any anti-tumor effect (Fig 6) . Confluent cultures of Hep3B cells were transduced with AGVhTRAIL and Ar6pAE2fE3F at the indicated PPC. When the CPE was evident, CVL was prepared and used to transduce a second round of confluent Hep3B cultures. After 24 hours, cell lysates were prepared, and the concentration of TRAIL was determined by ELISA. The detection limit of the assay was 0.36 pg TRAIL/mg protein.
In addition to decreasing tumor growth rate, AGVh-TRAIL used in a potentiating vector strategy increased the median duration of time animals were on study (95 days) from HBSS (24 days) or Addl312 (20 days; Table 2 ). At study day 58, 100% of animals treated with Ar6pAE2fE3F þ AGVhTRAIL remained on study compared to 7% of animals treated with HBSS or Addl312 and 67% of animals treated with Ar6pAE2fE3F only (Po.05). The combination of AGVhTRAIL with Ar6pAE2fE3F was the only vector treatment that significantly increased the number of animals remaining on study at study end relative to HBSS (Po.05). These animals had tumors that had either regressed completely, or dormant tumors that had partially regressed to less than 100 mm 3 . Ar6pAE2fmGMF or the combination of Ar6pAE2-fE3F and AGVmGMF in a potentiating vector strategy produced nearly identical results with regard to tumor growth. To assess the relative amounts of GMCSF produced from each strategy, serum and tumor GMCSF concentrations were determined (Fig 7) . The combination of Ar6pAE2fE3F and AGVmGMF induced only onesixth the amount of GMCSF in tumors relative to Ar6pAE2fmGMF. Furthermore, GMCSF was detectable in the serum of 12 of the 15 mice that received Ar6pAE2fmGMF, while GMCSF serum levels were below the detection limit of the assay in mice that received Ar6pAE2fE3F þ AGVmGMF. Interestingly, examination of tumor concentrations of TRAIL did not indicate any difference between tumors that received vectors encoding TRAIL and those that did not (data not shown).
Discussion
Tumor-selective, RC oncolytic adenoviral vectors provide a promising new therapy for cancer treatment. In this work, we investigated whether the antitumor efficacy of an oncolytic vector could be potentiated by coadministration of a gutless vector encoding GMCSF or TRAIL. We demonstrated that the delivery of an RC oncolytic vector with an RD gutless vector carrying a therapeutic transgene might significantly increase the efficacy of either system alone. The primary limitation of cancer Pre-established Hep3B tumors growing subcutaneously in nude mice received five intratumoral injections of the indicated vectors (n ¼ 15). Addl312, Ar6pAE2fE3F and Ar6pAE2fmGMF were administered at 2 Â 10 7 ppi; AGVmGMF and AGVhTRAIL were administered at 0.5 Â 10 7 ppi; in combination with Ar6-pAE2FE3F, and AGUhTRAIL was administered at 2 Â 10 7 ppi, alone. Animals were removed from study and euthanized when tumor volumes exceeded 2000 mm 3 or when animals became moribund. The study was terminated when all animals harbored tumors less than 100 mm 3 or were tumor-free, that is, complete or partial tumor regression. * # based on log-rank test of KaplanMeier survival curves, Po.05. Po.05 versus. (a) Ar6pAE2fE3F, (b) Ar6pAE2fE3F+AGVmGMF, (c) Ar6pAE2fE3F+AGVhTRAIL on the same day using Fisher's exact test. In agreement with these in vitro findings, the authors also showed that in vivo administration of an RC vector with the IL-2-expressing RD vector increased efficacy relative to the RD vector alone in a pancreatic tumor xenograft model. Taken together, these observations suggest that an oncolytic vector could increase the therapeutic potential of an RD gutless vector by amplifying the initial gutless vector input and increasing transgene expression.
Inclusion of a therapeutic gene, such as GMCSF, into an oncolytic vector was recently demonstrated to increase in vivo efficacy. 13 It is, therefore, of interest whether utilizing multiple genes to target other pathways would provide additional therapeutic benefit. However, packaging constraints on the size of the vector genome and the detrimental effects of deleting viral genes on vector efficacy likely preclude the inclusion of multiple transgenes within an oncolytic vector. The current experiments revealed that expression of GMCSF, whether from AGVmGMF when coadministered with Ar6pAE2fE3F or from Ar6pAE2fmGMF, resulted in a similar reduction in tumor growth rate relative to Ar6pAE2fE3F. It is unclear how GMCSF functioned in immunocompromised nude mice, which lack functional B cells and T cells. However, the enhanced efficacy of treatment regimens containing GMCSF-expressing vectors suggests that, in addition to inducing adaptive antitumor responses, GMCSF may also stimulate innate mechanisms of antitumor immunity. These data provide evidence that delivery of a therapeutic transgene via a gutless vector in combination with an oncolytic vector can be as efficacious as direct inclusion of the gene in an oncolytic vector. Perhaps not surprisingly, even better efficacy was observed with AGVhTRAIL. TRAIL is a type II transmembrane protein, which induces apoptosis directly via binding to cognate cell-surface receptors. Therefore, TRAIL function should not be diminished in an immunocompromised animal model. When administered with Ar6pAE2fE3F, AGVhTRAIL reduced tumor growth rate and increased the number of animals remaining on study at day 58 compared to treatment with Ar6pAE2fE3F alone. The increased efficacy observed with coadministration of AGVmGMF or AGVhTRAIL with Ar6pAE2fE3F supports the development of gutless vectors as potentiating vectors for oncolytic vector therapy, which could permit the expression of multiple therapeutic genes to further potentiate tumor cell erradication.
Interestingly, we found that the ratio of oncolytic to gutless vector administered was critical. While a 4:1 (oncolytic to gutless) ratio was efficacious, a 1:1 ratio was not. A possible explanation for this observation is that since the oncolytic and gutless vectors share the same replication machinery, supplied by the oncolytic vector, an increased ratio of gutless vector may have inhibited oncolytic vector replication.
While administration of a two-vector system for tumor therapy poses complications for clinical applications and product manufacture, such a potentiating vector strategy may provide safety advantages over expressing a transgene from an oncolytic vector. Despite the fact that the combination of AGVmGMF plus Ar6pAE2fE3F produced the same effect on tumor growth as Ar6-pAE2fmGMF, treatment with AGVmGMF plus Ar6pAE2fE3F resulted in one-sixth the concentration of GMCSF in tumors and undetectable levels of GMCSF in serum. In contrast, 12 of 15 mice that received Ar6pAE2fmGMF had detectable levels of GMCSF in serum. Therefore, in certain situations, it may be possible to titrate transgene expression to increase safety without losing efficacy. Greater safety might be achieved with a potentiating vector strategy by utilizing tumor-specific and/or regulated promoters in a gutless vector or by adjusting the amount of gutless vector administered.
We chose TRAIL as a potential therapeutic gene for several reasons. Foremost, TRAIL induces apoptosis in tumor cells via binding to cognate cell-surface receptors, 19, 20 and the protein can be proteolytically processed, causing release of the extracellular portion of the molecule which remains cytotoxic. 28 Because TRAIL is membranebound and can also be released to diffuse away from the producer cell, TRAIL expression produces a therapeutic bystander effect. 29 Therefore, transduction of every cell within a tumor is theoretically not necessary for complete tumor erradication. Unlike other members of the TNF family such as TNF-a and Fas ligand (FasL), which are cytotoxic to both normal and tumor cells, TRAIL is reported to display tumor cell-selective induction of apoptosis. 21, 22 Administration of recombinant, soluble TRAIL to mice displayed antitumor activity without systemic toxicity. 21, 30 For these reasons, treatment of cancer with recombinant, soluble forms of TRAIL has been proposed. However, full-length TRAIL expressed locally from a gene therapy vector may be advantageous relative to treatment with recombinant, soluble TRAIL. Soluble TRAIL has a short half-life in serum, estimated to be 32 minutes in cynomolgus monkeys. 21 This fact would most likely necessitate frequent or continuous administration of the recombinant protein. Additionally, for reasons that are not entirely clear, many tumor cells seem to be resistant to the cytotoxic effects of TRAIL. Expression of full-length TRAIL from an adenoviral vector overcame the resistance of certain prostate cancer cell lines to cell-killing by soluble TRAIL. 31 In our experiments, transduction of Hep3B cells in vitro with AGVhTRAIL was more effective in killing cells than treatment with up to 250 ng/ml of soluble TRAIL. Taken together, these observations suggest that endogenous production of full-length TRAIL, mediated by an adenoviral vector, may be superior to administration of recombinant, soluble TRAIL.
In our Hep3B xenograft model, coadministration of AGVhTRAIL with Ar6pAE2fE3F provided greater antitumor efficacy relative to Ar6pAE2fE3F alone. Interestingly, increased TRAIL expression was not detected in tumors after two intratumoral injections with AGVh-TRAIL, with or without Ar6pAE2fE3F. The reasons for this observation are not clear from these experiments. It is possible that tumors were not harvested at the correct time to observe TRAIL expression from the vector. It is also possible that the cytotoxic activity of TRAIL might prevent accumulation of the protein within the tumor by killing cells that express it. The increased antitumor efficacy observed when AGVhTRAIL was administered as a potentiating vector, however, indicates the biological activity of TRAIL expressed from the vector and suggests that TRAIL may be efficacious when expressed from a gutless vector in a potentiating vector strategy.
In neither tumor study did treatment with a gutless vector alone slow tumor growth. This result was somewhat surprising for AGVhTRAIL given the direct apoptotic effects of TRAIL. Intratumoral delivery of RD adenoviral vector expressing the full-length TRAIL protein inhibited the growth of pre-established ALVA 31 prostatic carcinoma xenografts. 32 This vector contained the CMV promoter driving expression of TRAIL, rather than the EF-1a promoter, and was delivered at 10 9 plaque-forming units, well above the dose used in our study of five injections of 2 Â 10 7 total particles/injection. Whether these two differences in study design are responsible for the observed difference in efficacy is uncertain. What is evident from our study is that a dose of AGVhTRAIL that was nonefficacious alone augmented the efficacy of an oncolytic vector when the two vectors were administered together.
The experiments presented here suggest that a potentiating vector strategy, which combines the benefits of an RD gutless adenoviral vector with those of an oncolytic adenoviral vector, can overcome limitations associated with the use of either vector system alone. Our data indicate that the presence of an RC oncolytic vector could serve to increase transgene expression from a gutless vector within a tumor by allowing replication and propagation of the gutless vector. Likewise, the limited coding capacity of oncolytic adenoviral vectors can be overcome by coadministration of a potentiating gutless adenoviral vector, thereby allowing cancer gene therapies to utilize multiple antitumor strategies. It will be of interest to determine what effect the expression of multiple therapeutic transgenes from a single potentiating gutless vector would have on the therapeutic efficacy of an oncolytic vector.
